EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

GLP-1 analogues in patients with type 2 diabetes and chronic kidney disease: Benefits beyond glycemic control

Rodrigo Gonçalves Corrêa, Vitória Aparecida Cunha, Marcella Culau Vieira, Mateus de Paula Fonseca Damacena, Natália Elisabeth Wagner Müller, Rafaela dos Santos Bertagli, Rafael Pedro Roewer

International Health Sciences Review · 17.08.2026 · 2 (4)

DOI: 10.70164/ihsr.v2i4.211 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Health Sciences Review, online erschienen am 17.08.2026. Verfasst von Rodrigo Gonçalves Corrêa und 6 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Type 2 diabetes and chronic kidney disease form a high-risk cardiorenal phenotype in which treatment goals extend beyond reduction of glycated hemoglobin. This structured narrative, critical, and descriptive review examined PubMed/MEDLINE, the Cochrane Library, and current American Diabetes Association and Kidney Disease: Improving Global Outcomes guidance, prioritizing evidence published from 2011 through August 2026 and including older landmark publications when required. Early cardiovascular outcome trials suggested that glucagon-like peptide-1 receptor agonists reduced albuminuria and atherosclerotic events, but most kidney composites were dominated by new macroalbuminuria and were not designed to test kidney failure. The FLOW trial materially strengthened the evidence by showing that weekly semaglutide reduced clinically important kidney and cardiovascular outcomes and slowed estimated glomerular filtration rate decline in patients with albuminuric chronic kidney disease. Benefits probably arise from combined effects on weight, blood pressure, vascular risk, inflammation, oxidative stress, and renal sodium handling rather than glucose lowering alone. Current evidence supports use of agents with demonstrated benefit within layered therapy that also includes renin-angiotensin system blockade, sodium-glucose cotransporter 2 inhibition, and, when indicated, finerenone. Clinical application requires gradual dose escalation, attention to gastrointestinal intolerance and volume depletion, and individualized decisions in advanced kidney disease.

Zitieren

APA

Corrêa, R. G., Cunha, V. A., Vieira, M. C., Damacena, M. D. P. F., Müller, N. E. W., Bertagli, R. D. S., & Roewer, R. P. (2026). GLP-1 analogues in patients with type 2 diabetes and chronic kidney disease: Benefits beyond glycemic control. International Health Sciences Review, 2(4). https://doi.org/10.70164/ihsr.v2i4.211

Vancouver

Corrêa RG, Cunha VA, Vieira MC, Damacena MDPF, Müller NEW, Bertagli RDS, et al. GLP-1 analogues in patients with type 2 diabetes and chronic kidney disease: Benefits beyond glycemic control. International Health Sciences Review. 2026;2(4). doi:10.70164/ihsr.v2i4.211

BibTeX
@article{Corra2026,
  author = {Corrêa, Rodrigo Gonçalves and Cunha, Vitória Aparecida and Vieira, Marcella Culau and Damacena, Mateus de Paula Fonseca and Müller, Natália Elisabeth Wagner and Bertagli, Rafaela dos Santos and Roewer, Rafael Pedro},
  title = {GLP-1 analogues in patients with type 2 diabetes and chronic kidney disease: Benefits beyond glycemic control},
  journal = {International Health Sciences Review},
  year = {2026},
  volume = {2},
  number = {4},
  doi = {10.70164/ihsr.v2i4.211}
}
Kostenlos starten →